{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:05:41Z","timestamp":1766088341350,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1R01DK131064-01","1R01 DK117965-01A1"],"award-info":[{"award-number":["1R01DK131064-01","1R01 DK117965-01A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jlr.2024.100649","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T20:08:30Z","timestamp":1726776510000},"page":"100649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gly-\u03b2-MCA is a potent anti-cholestasis agent against \u201chuman-like\u201d hydrophobic bile acid-induced biliary injury in mice"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4196-0406","authenticated-orcid":false,"given":"Mohammad Nazmul","family":"Hasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung Dai","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirish K.","family":"Palle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianglei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiangang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2024.100649_bib1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"339","author":"Trauner","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2024.100649_bib2","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.2174\/092986706778521823","article-title":"Modulation of hepatocyte apoptosis: cross-talk between bile acids and nuclear steroid receptors","volume":"13","author":"Sola","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jlr.2024.100649_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellwent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2024.100649_bib4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100649_bib5","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jlr.2024.100649_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2024.100649_bib7","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100649_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2024.100649_bib9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug Therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jlr.2024.100649_bib10","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2024.100649_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1194\/jlr.RA119000395","article-title":"Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition","volume":"61","author":"Honda","year":"2020","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2024.100649_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcmgh.2020.12.004","article-title":"Cholangiopathy and biliary fibrosis in Cyp2c70-deficient mice are fully reversed by ursodeoxycholic acid","volume":"11","author":"de Boer","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2024.100649_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100261","article-title":"Ileal bile acid transporter inhibition in Cyp2c70 KO mice ameliorates cholestatic liver injury","volume":"63","author":"Truong","year":"2022","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2024.100649_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100340","article-title":"Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice","volume":"64","author":"Hasan","year":"2023","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2024.100649_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.jlr.2024.100649_bib16","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jlr.2024.100649_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jlr.2024.100649_bib18","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3390\/cells12101371","article-title":"Glycine-beta-Muricholic acid improves liver fibrosis and gut barrier function by reducing bile acid pool size and hydrophobicity in male Cyp2c70 knockout mice","volume":"12","author":"Hasan","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jlr.2024.100649_bib19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-2275(20)38331-0","article-title":"Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions","volume":"30","author":"Heuman","year":"1989","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2024.100649_bib20","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.3748\/wjg.15.5326","article-title":"Usefulness of a scoring system in the interpretation of histology in neonatal cholestasis","volume":"15","author":"Lee","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jlr.2024.100649_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A\u00a0simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J.\u00a0Basic Clin. Pharm."},{"key":"10.1016\/j.jlr.2024.100649_bib22","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1053\/j.gastro.2006.02.012","article-title":"Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity","volume":"130","author":"Hubbard","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2024.100649_bib23","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1194\/jlr.M200260-JLR200","article-title":"Molecular cloning and expression of rat liver bile acid CoA ligase","volume":"43","author":"Falany","year":"2002","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2024.100649_bib24","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/hep.25797","article-title":"Specific bile acids inhibit hepatic fatty acid uptake in mice","volume":"56","author":"Nie","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100649_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/2191-219X-3-60","article-title":"Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT","volume":"3","author":"Padmanabhan","year":"2013","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.jlr.2024.100649_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3348\/kjr.2013.14.1.45","article-title":"Establishment of a protocol for determining gastrointestinal transit time in mice using barium and radiopaque markers","volume":"14","author":"Myagmarjalbuu","year":"2013","journal-title":"Korean J. Radiol."},{"key":"10.1016\/j.jlr.2024.100649_bib27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/003655202760230955","article-title":"Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers","volume":"37","author":"van Gorkom","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jlr.2024.100649_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10713","article-title":"Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis","volume":"7","author":"Gomez-Ospina","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jlr.2024.100649_bib29","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1097\/MPG.0000000000002670","article-title":"NR1H4-related progressive familial intrahepatic cholestasis 5: further evidence for rapidly progressive liver failure","volume":"70","author":"Himes","year":"2020","journal-title":"J.\u00a0Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.jlr.2024.100649_bib30","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.12998\/wjcc.v9.i15.3631","article-title":"Progressive familial intrahepatic cholestasis - farnesoid X receptor deficiency due to NR1H4 mutation: a case report","volume":"9","author":"Czubkowski","year":"2021","journal-title":"World J. Clin. Cases"}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227524001548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227524001548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T16:15:52Z","timestamp":1735661752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227524001548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0022227524001548"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2024.100649","relation":{},"ISSN":["0022-2275"],"issn-type":[{"type":"print","value":"0022-2275"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gly-\u03b2-MCA is a potent anti-cholestasis agent against \u201chuman-like\u201d hydrophobic bile acid-induced biliary injury in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2024.100649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100649"}}